Research & Education
CURE Expert Connections
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Friday Frontline: June 7, 2019
From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.
FDA Grants Fast Track to Momelotinib for Intermediate/High-Risk Myelofibrosis
Kristie L. Kahl
The Food and Drug Administration granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.
FDA Approves Jakafi for the Treatment of Patients with Acute Graft-Versus-Host Disease
The FDA has approved Jakafi, the first and only treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients aged 12 years and older.
Friday Frontline: May 24, 2019
From World Blood Cancer Day to today’s top performers fundraising for lifesaving research, here’s what’s making headlines in the cancer space this week.
Survey Shows Split Between Blood Cancer Detection: Symptom Evaluation vs. Incidental Finding
Kristie L. Kahl
Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.
Patient Registry Provides Unique Insight Into Myeloproliferative Neoplasms
A new analysis of the myMPN Patient Registry has led to some exciting new discoveries, according to researchers.
U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis
Beth Fand Incollingo
The U.S. Food and Drug Administration (FDA) will give a priority review to the experimental targeted drug fedratinib as a potential treatment for the blood cancer myelofibrosis.
Small Actions Make a Big Difference in the MPN Community
Any action, larger or small, can make a major impact in the lives of patients with a myeloproliferative neoplasm.
Turning Love for Family Into Cancer Research
After her daughter was diagnosed, Celia Miltz founded the Friends of ET Research.
Expert Discusses Exciting Advances in the MPN Field
Angela Fleischman, M.D., Ph.D.
Angela Fleischman, M.D., Ph.D., is particularly excited for improvements in treating early-stage disease.
Not a member?
Sign up now!
Continue without login
OPTIONAL INFORMATION: The following information helps us tailor CURE to fit your needs
Please type below what best describes your interests and click on the selection(s):
I am a:
Please list other: